You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The kit, which received EUA from the FDA in May, will be used to test clinical samples from patients at D-HH member hospitals.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
UCSF's test, developed with Mammoth Biosciences, uses CRISPR technology, while the tests from the Broad Institute and BioSewoom are PCR-based.
The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
Sherlock Bio recently received US Food and Drug Administration Emergency Use Authorization for the kit, which uses CRISPR to detect the virus in patient samples.
In a study published last month, Mammoth demonstrated the technology's sensitivity, specificity, and speed compared to PCR-based COVID-19 testing.
The company said its test, which provides results in approximately one hour, is the first instance of CRISPR technology being authorized by the FDA.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.